MedTrace Logo

Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis

NCT00804934 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2012-05-28

No results posted yet for this study

Summary

The purpose of this study is to determine whether people who have received intermittent anti-VEGF therapy have an improvement in vision after being switched to monthly injections of Lucentis.

Conditions

Interventions

DRUG

Lucentis

0.5mg Lucentis every four months

Sponsors & Collaborators

  • Retina Institute of Hawaii

    lead OTHER

Principal Investigators

  • Debra L Shimabukuro, RN · Retina Institute of Hawaii

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2008-02-29
Completion
2009-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00804934 on ClinicalTrials.gov